Dear Friends and Investors,

We’re excited to invite you to a private, invitation-only investor meeting featuring Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapies that resolve systemic inflammation — unlocking the healthspan, longevity revolution.

Sen-Jam’s proprietary PAIR (Pleiotropic Anti-Inflammatory Regulators) platform pairs well-characterized NSAIDs with immune modulators (e.g., mast cell stabilizers) to shut down upstream inflammatory cascades. By targeting inflammation and neuroinflammation at the source, Sen-Jam is advancing novel combination therapeutics across pain and CNS, respiratory/critical care support, metabolic disease, addiction, and healthy aging.

This elegant, de-risked approach bridges biotech rigor with scalable clinical utility — positioning Sen-Jam as a category creator in systemic inflammation resolution.

The Investment Opportunity:

• Now raising: $1.3M
• Minimum investment: $25,000 (lower amounts may be considered at Management’s discretion)
• Early participation: Investors within 30 days receive preferential terms
• Path to scale: 505(b)(2) strategy leveraging existing safety data; near-term clinical catalysts
  
  

Why Sen-Jam?

Validated Science, Clinical Momentum

• SJP-001 entering Phase 2 for alcohol-induced inflammation (targeting upstream drivers of pain and systemic stress).
• SJP-002C, an innovative anti-inflammatory therapy for respiratory inflammation, recently completed a Phase 2 study with Duke University and this year expanded therapeutic value into Metabolic Disorders including Obesity/MASH
• Platform supported by scientific publications/data packages and 505(b)(2) pathway advantages.

Massive, Underserved Need

• Inflammation and neuroinflammation are the common axis across multi-billion-dollar markets: age-related diseases, pain/CNS, infectious/respiratory, metabolic (metaflammation), addiction, and longevity (inflammaging(. The opportunity is to move medicine from symptomatic relief to systemic resolution.

First-Mover Advantage

• A platform approach that modulates multiple inflammatory pathways (NF-κB, TLR4, cytokines, PG/LT/histamine) to address central sensitization and neuroinflammatory drivers — a differentiated route to durable clinical impact.

Experienced Leadership

• Jackie Iversen, R.Ph., MS (Co-founder & Chief Clinical Officer) — inventor of PAIR technology platform, visionary pharmacist and veteran of pharmacokinetics, pain management and clinical strategy.
• Jim Iversen (CEO & Co-Founder) — seasoned successful entrepreneur with over $80M in exits, YPO change maker and business strategist with value creation at the core
• Supported by a multidisciplinary advisory network across immunology, neuroscience, longevity, and regulatory strategy.
  
  

Why You Should Attend:

This is a rare opportunity to back a de-risked, platform-scale inflammation company with near-term readouts and multi-indication upside — and to meet the team shaping the next chapter of pain, CNS, and longevity care.

Join a select group of investors for an insider’s view into Sen-Jam’s pipeline, clinical milestones, and commercialization strategy.

Event Details:

Location: Online via Zoom

Date: October 29, 2025

Time: 11:30am EDT

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

RSVP now to secure your seat and request investment materials by contacting Skylar Rallison at srallison@opus8.com

We look forward to hosting you and exploring how resolving systemic inflammation can unlock the next era of healthspan and clinical value.

Warm regards,

Tien Wong

CEO

The Opus8 Team